A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

计划入组 301 人 · 首次发布于 2021 年 3 月 4 日

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

计划入组 153 人 · 首次发布于 2021 年 9 月 2 日

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

计划入组 174 人 · 首次发布于 2022 年 11 月 25 日

HZN-457

HZN-002

HZN 003

JUUL LABS, INC.

United States

IDIENCE CO., LTD.

South Korea

Douglas Mental Health University Institute

Canada

Systemic Sclerosis Pipeline Shows Promise with 50+ Therapies in Development

Kriya Therapeutics Presents Promising Preclinical Data for KRIYA-825 Gene Therapy in Geographic Atrophy

Beta Technologies Files for $825 Million IPO to Fund Electric Aircraft Development